Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 2/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 16/20 | 0.36 |
| ▸ | CDK9 | P50750 | 16/20 | 0.36 |
| ▸ | KIT | P10721 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CDK7 | P50613 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2996531 | 0.96 | IGF1R (0.38) | IGF1RCCNT1CDK9KIT | |
| SCHEMBL2991596 | 0.95 | IGF1R (0.36) | IGF1RCCNT1CDK9KIT | |
| SCHEMBL2993246 | 0.93 | IGF1R (0.36) | IGF1RCCNT1CDK9KIT | |
| SCHEMBL2996058 | 0.93 | IGF1R (0.37) | IGF1RCCNT1CDK9KIT | |
| SCHEMBL5540142 | 0.92 | CCNT1 (0.36) | IGF1RCCNT1CDK9JAK2 | |
| SCHEMBL2987049 | 0.91 | CCNT1 (0.43) | IGF1RCCNT1CDK9KIT | |
| SCHEMBL1748812 | 0.90 | IGF1R (0.49) | IGF1RCCNT1CDK9KITJAK2 | |
| SCHEMBL2993805 | 0.90 | CCNT1 (0.39) | IGF1RCCNT1CDK9 | |
| SCHEMBL1749151 | 0.86 | IGF1R (0.47) | IGF1RCCNT1CDK9KITJAK2 | |
| SCHEMBL2994861 | 0.86 | IGF1R (0.39) | IGF1RCCNT1CDK9JAK2LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799691-B1 | NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2011-12-21 | — | — | EP | disclosed |
| US-20100256141-A1 | NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2010-10-07 | — | — | US | disclosed |
| US-7786114-B2 | Bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2010-08-31 | — | — | US | disclosed |
| US-20080045561-A1 | Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-02-21 | — | — | US | disclosed |
| EP-1799691-A1 | NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006037875-A1 | NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045561-A1 | Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors | BRSK2, KSR2, CDK2 | IGF1R 606/4885CCNT1 327/4885CDK9 90/4885 |
| US-20100256141-A1 | NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | BRSK2, KSR2, CDK2 | IGF1R 606/4885CCNT1 327/4885CDK9 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.